Sponsored Content by PREDiCTOct 29 2019
At this year’s 2nd RNA-Targeted Drug Discovery Summit, held in Boston from the 2nd of December to the 4th, 2019, an expert panel will provide visitors with the opportunity to pose their questions to RNA community leaders in order to develop valuable strategies with the aim of advancing the translation of safe, targeted, and robust RNA-targeted small molecules into clinical trials.
Jane Withka, Director & Collaboration Lead at Pfizer Worldwide R&D, Yochi Slonim, Co-Founder & CEO of Anima Biotech, Kathryn McCabe, Senior Director of Business Development in Emerging Technology & Innovation, Eli Lilly, Jennifer Petter, the Founder & CSO of Arrakis Therapeutics, and Christopher Barbieri, the Senior Investigator at Bristol-Myers Squibb, will head up this the industry-led panel discussion.
Visitors to the 2nd RNA-Targeted Drug Discovery Summit will be able to discover how to establish strategies and standards to provide clear guidance on how to intentionally target RNA with small molecules; how mRNA and its regulatory mechanisms can enable new strategies against previously undruggable targets; and gain insight into the right approach in this broad and novel target space.
There will also be opportunities to explore how the research field might be influenced by pharma, in particular the strategies for emerging platform companies in the RNA field for effective partnering.
Register here and join the 2nd RNA-Targeted Drug Discovery Summit 2019 to hear five world-class leaders discuss these critical challenges and stay ahead of the curve.
Over 100 key leaders from Biogen, Sanofi, Skyhawk Therapeutics, Remix Therapeutics, Twentyeight-Seven Therapeutics and more are coming together in Boston December 2019 to drug the undruggable RNA at last.
Book a place now.
About PREDiCT
The hard reality of drug development is a rising rate of attrition and development costs.
Dedicated to exploring the latest advances in the application of preclinical models, the PREDiCT Event Series is helping to fight back and make inroads in the ‘war on attrition’ by showcasing candidate selection strategies advancing disease modifying therapies from bench to patient with more confidence.
Focused predominantly on immunogenic, fibrotic and oncogenic diseases, we connect expert model developers alongside end users and technology champions from biopharma, to define what’s possible for current and emerging in vitro/in vivo models.
Our disease and model specific events, reveal effective model characterization and selection strategies that are better enabling drug candidates to target patient responders, identify safety concerns and robustly translate candidates to clinic faster.
The core questions to be answered at every PREDiCT: Tumor Models meeting:
- What new model and additive technology initiatives are helping biopharma leaders drive translational and early-stage decision making?
- How do biopharma leaders balance advances in model complexity and relevance with the cost-per-data-point?
- What are the key criteria the leading biotech and pharma use to assess, select and characterize the array of tumor models?
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.